MIAMI--(BUSINESS WIRE)-- Vector Group Ltd. (NYS: VGR) ("Vector" or the "Company") today announced the pricing of its previously announced public offering of $200.0 million aggregate principal amount ...
We previously published a report on the scale-up and manufacturing of clinical-grade SIN gRV vectors by transient transfection in a closed-system bioreactor in which we identified optimized ...
Furthermore, our recent demonstrations that overexpression of cathepsin L in human tumor cells is under the control of separate and complex regulatory mechanisms 20, 21 support that procathepsin L ...